ART Assisted Reproductive Technologies Market Research Report Based on Size, Manufacturers, Type, Regions and Forecast to 2028

Emerging research logo

Excessive alcohol consumption, smoking, stress, delayed marriages, and strenuous workouts and sports lead to increased rates of infertility

Assisted Reproductive Technology (ART) Market Size – USD 25.95 Billion in 2020, Market Growth – at a CAGR of 9.7%, Market Trends – Technological Advancements »

— Emerging research

VANCOUVER, BC, CANADA, July 11, 2022 /EINPresswire.com/ — The Global Assisted Reproductive Technology (ART) Market the size is expected to reach USD 54.75 billion with a stable revenue CAGR of 9.7% in 2028, according to the latest analysis from Emergen Research. Revenue growth of the Assisted Reproductive Technology (ART) market is driven by the growing popularity of in vitro fertilization (IVF) (with or without intracytoplasmic sperm injection (ICSI)) and artificial insemination, among other technologies .

Infertility is a multi-faceted problem involving social, cultural and economic implications, which can reach threatening proportions in countries with lower fertility rates. According to statistics published by the WHO, approximately 48 million couples and 186 million people live with infertility worldwide. The increasing incidence of ovulation problems with irregular or no periods is a common cause of infertility in women. Increased awareness of various fertility treatments among the younger generation and more women opting for such fertility treatments are driving the growth of the market.

Get a sample report @ https://www.emergenresearch.com/request-sample/165

The prevalence of infertility is higher among the male population across the world. Rising stress levels, shift to a sedentary lifestyle, and increasing incidence of obesity are leading to fertility issues, which propels the growth of the assisted reproductive technologies market. A major cause of infertility among the world’s population is sexually transmitted diseases (STDs), primarily gonorrhea and chlamydia. These diseases can damage or scar the fallopian tubes in women and block and scar reproductive structures (eg, the ejaculatory ducts), leading to infertility.

However, assisted reproductive procedures are expensive and most people in developing countries cannot afford them. Moreover, the social stigma regarding these procedures also hampers the market revenue growth.

The main companies studied in the report are:

Origio, Cryolab Ltd., Bloom IVF Center, Ferring Pharmaceuticals, Cosmos Biomedical, Irvine Scientific, European Sperm Bank, Ovascience, Parallabs and Microm UK Ltd.

Some highlights of the report

In June 2020, Ferring Pharmaceuticals announced a two-year collaboration with Igenomix for innovative disease mechanism research and target discovery in conditions associated with infertility and pregnancy, such as preeclampsia, to develop approaches breakthrough diagnostics and therapeutics to meet strong unmet demand. A new center in Boston has been created which will bring together experts from both companies and the objective is to study molecular structures, develop functional genomic systems and create tools to study embryo implantation, among others.

Ask for a discount on the report @ https://www.emergenresearch.com/request-discount/165

The revenue of frozen non-donor segment is expected to register a significantly rapid growth rate over the forecast period due to its established reliability and higher success rate for pregnancy. The cost of the procedure is lower than cycles using fresh embryos and eggs. A frozen transfer is much simpler for the reproductive endocrinologist and the patient. This procedure is also less mentally and physically stressful on a woman’s body.

The artificial insemination segment accounted for a significantly large revenue share in 2020 because it does not require removing eggs from the body, and therefore the procedure is far less invasive for women planning to conceive. In this treatment, sperm is placed directly into the uterus or cervix to achieve pregnancy. Also, the process is more cost effective than IVF because it does not require egg retrieval or laboratory monitoring.

The hospital segment accounted for a significantly robust revenue share in 2020. Factors such as well-equipped operating and surgical theatres, the presence of highly trained healthcare professionals, and improved health coverage for healthcare services of various Private and group insurance plans are factors that drive the provision of assisted reproductive technology in hospitals. However, a decrease in adoption of the latest and most innovative upgrades can lead to a decline in revenue share.

To learn more about the report, click @ https://www.emergenresearch.com/industry-report/assisted-reproductive-technology-market

Growth in revenue share of assisted reproductive technology market in Europe is driven by contribution from France, Germany and UK respectively. This can be attributed to increasing novelties in clinical practice and improved access to fertility treatments in countries in the region. In addition, the region is the first to remove the “experimental” label on egg cryopreservation. The choice to become pregnant after 30 years or more by European women creates a constant demand for assisted reproductive technologies.

Emergen Research has segmented the global assisted reproductive technology market based on procedure, technology, end-use, and region:

Procedural Outlook (Revenue, USD Billion; 2018-2028)

fresh donor

Fresh non-donor

Donor Frozen

Non-donor frozen

Egg/embryo bank

Technology Outlook (Revenue, USD Billion; 2018-2028)

In Vitro Fertilization (IVF)

In vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI)

In vitro fertilization (IVF) without intracytoplasmic sperm injection (ICSI)

Artificial insemination

Frozen Embryo Transfer (FET)

Others

End-Use Outlook (Revenue, USD Billion; 2018-2028)

Hospitals

Fertility clinics

Others

Request report customization @ https://www.emergenresearch.com/request-for-customization/165

Regional Outlook (Revenue, USD Billion; 2018-2028)

North America

WE

Canada

Mexico

Europe

Germany

UK

France

Spain

BENELUX

The rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East and Africa

Saudi Arabia

United Arab Emirates

Israel

Rest of MEA

The report addresses the following key points:

The report estimates the expected market size from 2020 to 2028

The report provides a forecast of market drivers, restraints, and future opportunities for the Assisted Reproductive Technology (ART) Market

The report further analyzes changing market dynamics

Regional analysis and market segmentation with analysis of regions and segments expected to dominate market growth

Comprehensive competitive landscape mapping with key competitor profiles

In-depth analysis of business strategies and collaborations such as mergers and acquisitions adopted by leading companies

Revenue forecast, country scope, application information and product information

Thank you for reading our report. For any specific details on customizing this report, please contact us. We will ensure that the report you get is well suited to your needs.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market strategy consulting and research firm with an extensive knowledge base on cutting-edge and potentially market-disrupting technologies that are expected to become more prevalent over the next decade.

Eric Lee
Emerging research
+16047579756 ext.
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn

Back To Top